A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced Adenocarcinoma of the stomach and Gastroesophageal junction

Oncologist

Volumn 21, Issue 9, 2016, Pages 1085-1090

  Shah, Manish A ^a   Cho, Jae Yong ^b   Tan, Iain B ^c   Tebbutt, Niall C ^d   Yen, Chia Jui ^e   Kang, Alice ^f   Shames, David S ^g   Bu, Lilian ^f   Kang, Yoon Koo ^h  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d AUSTIN HEALTH   (Australia)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f Roche Product Development in Asia Pacific   (China)

^g GENENTECH INC   (United States)

^h University of Ulsan   (South Korea)

Author keywords

Chemotherapy; First line; Gastric cancer; HER2 negative; MET; Onartuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; ONARTUZUMAB; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; SCATTER FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; GASTRECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; ESOPHAGUS TUMOR; GASTROESOPHAGEAL JUNCTION; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; STOMACH TUMOR; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84988025815     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0038     Document Type: Article

References (16)

1. Bray F, Ren JS, Masuyer E et al. Globalestimatesof cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-1145.
2. Waddell T, Verheij M, Allum W et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014;40:584-591.
3. Shah MA. Update on metastatic gastric and esophageal cancers. J ClinOncol 2015;33:1760-1769.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24:4991-4997.
5. Blumenschein GR Jr., Mills GB, Gonzalez-Angulo AM.Targetingthehepatocytegrowthfactor-cMETaxis in cancer therapy. J Clin Oncol 2012;30:3287-3296.
6. Ha SY, Lee J, Kang SY et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 2013;26:1632-1641.
7. Toiyama Y, Yasuda H, Saigusa S et al. Coexpression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2012;130:2912-2921.
8. Yu S, Yu Y, Zhao N et al. C-Met as a prognostic marker in gastric cancer: A systematic review and meta-analysis. PLoS One 2013;8:e79137.
9. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902.
10. Catenacci DV, Henderson L, Xiao SY et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011;1:573-579.
11. Iveson T, Donehower RC, Davidenko I et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 2014;15:1007-1018.
12. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-4810.
13. Koeppen H, Yu W, Zha J et al. Biomarkeranalyses from a placebo-controlled phase II study evaluating erlotinib6onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014;20:4488-4498.
14. Cunningham D, Tebbutt NC, Davidenko I et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as firstline therapy in patients (pts) with advanced METpositive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015; 33:. suppl; abstr 4000).
15. Penuel E, Li C, Parab V et al. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther 2013; 12:1122-1130.
16. Kwak EL, LoRusso P, Hamid O et al. Clinical activity of AMG337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G) or esophageal (E) cancer. J Clin Oncol 2015;33(suppl 3):abstr 1.